乳腺癌术后服用他莫昔芬对子宫内膜的影响研究

目的探讨乳腺癌术后服用他莫昔芬(TAM)对子宫内膜的病理影响。方法收集2011年1月至2017年12月首都医科大学附属北京妇产医院收治的乳腺癌手术治疗患者共622例,术后197例服用TAM,其中59例患者因异常阴道流血或超声子宫内膜异常行宫腔镜诊刮术,将其分为绝经前组及绝经后组,以服药时间3年及5年为界值,分析子宫内膜病理情况。子宫内膜异常增生包括子宫内膜癌、子宫内膜不典型增生,其余为良性子宫内膜病变及正常子宫内膜,根据子宫内膜病理结果分析绝经前及绝经后超声诊断异常子宫内膜增生的标准。结果乳腺癌术后服用TAM患者197例,其中59例行宫腔镜诊刮术,因异常阴道流血就诊者占32.2%(19/59),经病理证实有子宫内膜病变者占76.3%(45/59),其中子宫内膜息肉的发生率最高;绝经前子宫内膜癌发生率为3.4%(1/29),子宫内膜不典型增生发生率为20.7%(6/29);绝经后子宫内膜癌发生率为20.0%(6/30),无子宫内膜不典型增生的发生。TAM服用时间超过3年或5年,子宫内膜癌及不典型增生的发生率均增加(P0.05)。绝经前子宫内膜厚度与子宫内膜异常增生有关(P=0.035),当超声子宫内膜厚度达15mm时可作为诊断绝经前异常子宫内膜增生的最佳超声诊断阈值;而绝经后子宫内膜厚度与子宫内膜异常增生无关(P=0.631)。结论乳腺癌术后服用TAM能够引起子宫内膜息肉及子宫内膜增生,绝经前患者亦有子宫内膜癌及不典型增生的发生,不可忽视对服用TAM绝经前妇女子宫内膜的监测。服用TAM时间超过3年者,需更加警惕子宫内膜病变的发生。绝经前超声子宫内膜厚度15mm可作为诊断异常子宫内膜增生的最佳超声诊断阈值;绝经后仍以超声子宫内膜厚度5mm作为子宫内膜异常增生标准。     

绝经后乳腺癌患者服用他莫昔芬发生子宫内膜息肉危险因素的探讨

目的:探讨绝经后因乳腺癌服用他莫昔芬(TAM)与子宫内膜息肉发生的相关性。方法:随诊了46例绝经后服用TAM超过6个月的妇女,其中22例经宫腔镜手术及内膜病理证实为内膜息肉(A组),24例宫腔镜检查未发现息肉(B组)。比较2组服用TAM的时间、剂量,经阴道超声波(TVS)检查的结果,并分析与子宫内膜癌相关的危险因素。结果:息肉组妇女的体重明显重于非息肉组(P=0.013),且比非息肉组服用TAM的时间长,TAM的累计剂量增加(P值均为0.002)。经阴道超声波检查示息肉组子宫内膜增厚或者宫内异常回声的发生率明显高于非息肉组(P=0.019)。结论:肥胖,长期服用TAM超过2年或累计剂量超过15g是绝经后妇女服用TAM发生子宫内膜息肉的高危因素。TVS提示内膜增厚或者宫内异常回声有诊断价值,可作为预测内膜息肉发生的指标。     

三苯氧胺对子宫内膜的影响

目的：观察乳腺癌患者服用三苯氧胺（TAM）后对子宫内膜的影响。方法：26例乳腺癌患者服用TAM（TAM组）后出现阴道异常出血或B超检查发现子宫内膜增厚而行宫腔镜检查及子宫内膜病理检查。另外以同时期无TAM服药史的非乳腺癌患者因绝经后阴道出血而行宫腔镜检查的78例作为对照组。结果：TAM组发生子宫内膜息肉和宫颈息肉共13例（50.0%）,而对照组为14例（17.9%),两组比较,差异有显著性（P＜0.05)。TAM组发生子宫内膜增生9例（34.6%),明显高于对照组的12例（15.4%,P＜0.05)。结论：乳腺癌患者长期服用TAM后子宫内膜病变增多,故对这些患者应进行B超监测子宫腔镜检查。     

绝经后无症状子宫内膜增厚患者临床病理分析

目的:探讨绝经后妇女B超检查显示子宫内膜增厚而无症状者的子宫内膜病理变化。方法:对绝经后B超显示子宫内膜增厚无症状患者(无症状组)及同期绝经后B超显示子宫内膜增厚伴有阴道出血者(出血组)进行诊断性刮宫与病理检查结果比较。结果:无症状组子宫内膜增厚的86例患者中,非器质性病变44例(51.16%),良性病变42例(48.84%),无恶性及癌前病变;出血组子宫内膜增厚的79例中,非器质性病变48例(60.76%),良性病变17例(21.52%),恶性14例(17.72%)。无症状组随着年龄增大、绝经年限延长、内膜厚度增加,其良性病变呈上升趋势(P0.05);出血组随着年龄增大、绝经年限延长、内膜厚度增加,其恶性病变呈上升趋势(P0.05);其中无症状绝经后妇女B超示子宫内膜增厚者中内膜病变与内膜厚度和体质量指数(BMI)相关。结论:绝经后子宫内膜增厚不伴阴道出血时,多为良性病变,对于肥胖、内膜厚及绝经年龄较长患者更应重视。绝经后子宫内膜增厚伴有阴道出血时,恶性病变比例显著升高。     

宫腔镜协助诊断绝经后阴道流血223例临床分析

目的:探讨绝经后阴道流血的原因以及宫腔镜诊断的价值.方法:分析我院223例绝经后阴道流血病例的宫腔镜检查结果并与病理结果对照.结果:宫腔镜检查后经病理确诊引起绝经后阴道流血的原因中子宫内膜良性病变占83.4%,子宫恶性肿瘤占12.6%,宫内节育器占3.1%.绝经年限和恶性肿瘤有关.宫腔镜诊断与病理检查的符合率为87.0%.结论:宫腔镜协助下行活检或诊刮可明确绝经后阴道流血的原因,并可提高诊断准确率.     

绝经期乳腺癌妇女服用他莫昔芬后Ki-67及Bcl-2在子宫内膜中的表达

目的:评估绝经期乳腺癌妇女服用他莫昔芬(tamoxifen,TAM)后Ki-67及Bcl-2在子宫内膜中的表达。方法:46例绝经后因乳腺癌服用TAM超过6个月妇女的子宫内膜为研究组,行宫腔镜检查及内膜活检。18例因子宫脱垂行子宫切除的绝经后妇女的萎缩型子宫内膜为对照组。用免疫组化法测定Ki-67及Bcl-2在子宫内膜中的表达。结果:与对照组比较,Ki-67在TAM相关内膜腺上皮细胞呈显著高表达(15.41±4.83vs9.05±5.52,P=0.009);Bcl-2在TAM相关内膜腺上皮细胞呈较高表达,但与对照组比较无统计学差异(0.50±0.17vs0.43±0.11,P=0.077)。结论:绝经后乳腺癌妇女服用TAM能引起子宫内膜细胞增殖,但并不代偿性促进细胞凋亡,诱导细胞增殖是TAM对绝经后子宫内膜作用机理的一部分。     

绝经后妇女子宫出血经阴道超声和宫腔镜检查的比较

绝经后妇女子宫出血是子宫内膜癌的常见首发症状,子宫内膜活检可早期诊断。诊断子宫内膜癌的非侵入性的方法将替代传统的扩、刮宫手术方法。对28例绝经后妇女进行回顾性研究,评价宫腔镜检查、子宫内膜病理诊断和经阴道超声(TVS)的准确性。28例中绝经时间最短12个月,最长25年。无激素替代治疗史。其中2例正在服用他莫昔芬治疗乳癌。平均年龄57.8±7.2岁。全部进行TVS。采用5.0或7.5MHz阴道探头,双层测量法,以子宫内膜     

测定他莫西芬使用者子宫内膜厚度预测子宫内膜病变

本研究的目的是评价将阴道超声检查单独作为预测绝经妇女子宫内膜病变指标的价值,并确定需要进行子宫内膜病理学检查的子宫内膜厚度的数值。方法:接受他莫西芬治疗的乳腺癌患者中,超声检查子宫内膜厚度超过4mm或有阴道出血,均行宫腔镜检查并选择地进行子宫内膜活检。同时对子宫内膜的厚度、服用他莫西芬的时间以及子宫内膜的病理结果进行分析,统计学分析采用参数及非参数检验和多元回归分析。结果:163例绝经的乳腺癌患者,接受他莫西芬治疗(20mg/d)至少6个月,其中46例有阴道出血。子宫内膜厚度超过9mm者子宫内膜组织学检查异常率为60%显著高…     

释放左旋18甲基炔诺酮宫内节育器对三苯氧胺引起子宫内膜病变的治疗

目的　探讨释放左旋 18甲基炔诺酮宫内节育器 (LNG -IUD ,Mirena)对服用三苯氧胺的乳腺癌患者子宫内膜病变的疗效和不良反应。方法　对 2 7例绝经后乳腺癌患者 ,术后服用三苯氧胺 (1～ 10 8个月 )引起的子宫内膜增厚进行临床资料分析 ,经过宫腔镜及诊断性刮宫除外子宫内膜癌后 ,宫内放置Mirena ,每 1～3个月行阴道B超 1次 ,观察放置前后子宫内膜厚度的变化及不良反应。结果　 2 7例置Mirena患者 ,从放置前子宫内膜平均厚度 (1 30± 0 4 2 )cm ,到放置后 3、6及 12个月以上时 ,子宫内膜平均厚度分别为 (0 95± 0 2 9)cm、(0 93± 0 36 )cm及 (0 78± 0 2 2 )cm ,P值均 <0 0 1。不良反应主要为不规则阴道流血 ,但大多可自行停止。结论　释放左旋 18甲基炔诺酮宫内节育器对服用三苯氧胺绝经后乳腺癌患者增厚的子宫内膜具有治疗作用 ,不良反应轻微。左旋 18甲基炔诺酮可以保护服用三苯氧胺的绝经后乳腺癌患者的子宫内膜。     

宫腔镜在子宫内膜息肉诊断和治疗中的作用

本研究评定宫腔镜诊断和治疗绝经后妇女子宫内膜息肉的价值 ,并与 Rondall息肉摘除钳辅助刮宫术进行比较。对 83例绝经后妇女诊断前后进行宫腔镜检查和治疗 ,除诊刮并采用 Randall钳摘除子宫内膜息肉 ,刮宫和钳夹息肉由不知宫腔镜检查结果的另一组人员操作。结果 :83例中包括绝经后出血 (n=40 ) ,超声显示子宫内膜异常 (n=37)或两者兼有 (n=6 ) ,其中 32例接受激素替代治疗或他莫昔芬。术前宫腔镜检查发现子宫内膜息肉者 5 1例 ,而单行刮宫仅发现息肉 2 2例 ,此 2 2例中有 18例残留的息肉通过 Randall钳钳夹摘除 ,另外 2 3例息肉借助 Rand…     

Sonographic, hysteroscopic, and histologic evaluation of the endometrium in postmenopausal women with breast cancer receiving tamoxifen

STUDY OBJECTIVE: To evaluate the estrogenic effects of tamoxifen on the endometrium in postmenopausal women with breast cancer. DESIGN: Consecutive study (Canadian Task Force classification II-2). SETTING: University-affiliated hospital. PATIENTS: Thirty-three women. Interventions. All patients underwent transvaginal sonography (TVS) and color flow Doppler of endometrial vessels, hysteroscopy, and, if necessary, endometrial biopsy or other operative hysteroscopic procedures. MEASUREMENTS AND MAIN RESULTS: In four women the endometrium was thin on TVS and atrophic at hysteroscopic assessment. In 29 women with thick endometrium on TVS, hysteroscopy and endometrial biopsy showed atrophy (11 patients), hyperplasia (5), polyps (11), and well-differentiated adenocarcinoma (2). The two endometrial cancers were present in women with uterine bleeding. In women with positive histologic findings, the endometrium was significantly thicker (p = 0.04) and duration of tamoxifen therapy longer than in those with negative findings, although this was not statistically significant (p = 0.067). CONCLUSION: We believe regular assessment of the endometrium by TVS should be performed in postmenopausal patients at the start of the tamoxifen therapy, and hysteroscopy in women with a thick endometrium or postmenopausal bleeding. We believe that patients with thin endometrium on TVS at the beginning of tamoxifen therapy, who have no abnormal uterine bleeding should be screened with these examinations for 2 years.     

Transvaginal ultrasound and diagnostic hysteroscopy as a predictor of endometrial polyps: risk factors for premalignancy and malignancy

The aim of this study is to assess accuracy of transvaginal ultrasound (TVUS) and diagnostic hysteroscopy in diagnosing endometrial polyps and to determine premalignancy and malignancy rates in asymptomatic women. The study was designed to retrospectively analyze 438 women who underwent operative hysteroscopy in a day-care unit when endometrial polyp was suspected after TVUS and diagnostic hysteroscopy. Multivariate logistic regression modeling showed effects of age, previous breast cancer with tamoxifen treatment, and menopause with or without bleeding on pathologic results. The results indicate that positive predictive value of TVUS with diagnostic hysteroscopy was 79.9%. Premalignancy or malignancy occurred in 3.2% and was significantly related to menopause with abnormal bleeding (P < 0.001), which carried a 20-fold higher risk of pathology than any other group. Age was also a risk factor. It was concluded that TVUS with diagnostic hysteroscopy reliably evaluates endometrial polyps. The low incidence of endometrial tumors in asymptomatic (especially premenopausal) women suggests that their operative evaluation may not be cost effective. Larger studies are needed to support this tentative conclusion.     

Transvaginal sonography combined with saline contrast sonohysterography to evaluate the uterine cavity in patients with abnormal uterine bleeding and postmenopausal endometrium more than 5 mm

OBJECTIVES: To determine whether saline contrast sonohysterography (SCSH) gives additional information to that obtained by transvaginal sonography (TVS) for predicting endometrial abnormality in premenopausal, menopausal and postmenopausal patients with abnormal uterine bleeding and postmenopausal patients with endometrial thickness > 5 mm. METHODS: This was a prospective study at the Ege University Obstetrics and Gynecology Clinic in Izmir, Turkey. Patients presenting with abnormal bleeding related to uterine pathologies, postmenopausal patients with endometrial thickness more than 5 mm and scheduled for surgical treatment were prospectively included in our study conducted between 1 July, 2000 and 31 January, 2002. The uterine cavity was first evaluated with TVS in 53 premenopausal, menopausal, postmenopausal patients with abnormal uterine bleeding and postmenopausal patients whose endometrial thickness was > 5 mm measured by conventional ultrasound examination. SCSH was carried out later with the intention of establishing further surgical management (hysterectomy). Twenty of the patients had operative hysterectomy within the 1.5 year period of time. The presence of focally growing lesions and the type of lesion (endometrial polyp, submucous myoma, malignancy or unclear focal lesion) were noted at ultrasound examination and at hysteroscopy, and then hysterectomy material was examined by Ege University's Pathology Department which provided a detailed evaluation of the uterine cavity. RESULTS: Based on normal endometrial morphology alone, the results for detection of an abnormal uterine cavity were as follows: sensitivity of TVS 0.94, SCSH 0.97; specificity of TVS 0.56, SCSH 0.62; positive predictive value of TVS 0.79, SCSH 0.81; negative predictive value of TVS 0.83, SCSH 0.93. Transvaginal sonography combined with SCSH was superior to TVS for detection of intracavitary abnormalities. When normal endometrial morphology was combined with an endometrial thickness of < 12 mm for evaluation of all abnormalities including hyperplasia, the diagnostic potential of TVS or SCSH was almost unchanged. Transvaginal sonography missed 24% of the polyps. CONCLUSIONS: Sonohysterography was a sensitive tool and was superior to TVS used alone for evaluation of the uterine cavity in patients who underwent operative surgery for abnormal uterine bleeding.     

Saline sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients taking tamoxifen.

OBJECTIVES: To evaluate the effectiveness of sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients on long-term tamoxifen therapy. METHODS: Thirty-eight asymptomatic postmenopausal patients receiving tamoxifen for breast cancer were enrolled into the study. The endometrium of study subjects was measured by transvaginal ultrasound. If a distinct echo measured < or = 5 mm, no further procedure was performed. For thickened or inadequately visualized endometrium by transvaginal ultrasound (TVS), sonohysterography was performed. Endometrial biopsies were performed for patients with generalized symmetrical changes on sonohysterography. In cases with focal changes, or inadequate SHG, hysteroscopy/dilatation and curettage (D&C) were performed. RESULTS: Transvaginal ultrasound examination showed 12 (31.6%) patients with thin endometrium < or = 5 mm, 18 (47.4%) cases with thickened endometrium while eight (21%) cases were not adequately visualized by TVS. Sonohysterography was satisfactorily performed in 22 of 26 (84.6%) cases. Of these, three cases showed thin endometrium, 10 patients had endometrial polyps (45.5%) and nine patients showed abnormal endometrial-myometrial junction. Histology revealed hyperplasia in three cases and well differentiated adenocarcinoma associated with one polyp. Endometrial curettage for cases with abnormal endometrial-myometrial junction showed endometrial hyperplasia in two cases. Hysteroscopy and D&C were performed for four (15.4%) patients where SHG was unsuccessful, histopathology revealed inactive endometrium in three cases and one was hyperplastic. CONCLUSIONS: Sonohysterography is superior to unenhanced transvaginal sonography in specifying the abnormal ultrasonographic appearance induced by prolonged tamoxifen therapy, it is easily performed, cost-effective and very well tolerated by the patients with no complications. Sonohysterography is recommended as a minimally invasive diagnostic tool for the assessment of endometrial changes in asymptomatic postmenopausal breast cancer patients on long-term tamoxifen therapy with thickened endometrium or inadequately visualized endometrial echo on transvaginal sonography.     

Accuracy of preoperative diagnostic tools and outcome of hysteroscopic management of menstrual dysfunction

STUDY OBJECTIVES: To review diagnoses, complications, and surgical findings in women treated for abnormal uterine bleeding by operative hysteroscopy, and to assess the accuracy of preoperative transvaginal ultrasound (TVS), saline-infusion sonography (SIS), diagnostic hysteroscopy, and endometrial biopsy. DESIGN: Retrospective study (Canadian task force classification II-2). SETTING: Tertiary care academic medical center. PATIENTS: Three hundred seventy-five women. Intervention. Operative hysteroscopy for abnormal uterine bleeding. MEASUREMENTS AND MAIN RESULTS: Main indications for hysteroscopy were postmenopausal bleeding (164 patients, 43.7%) and abnormal premenopausal uterine bleeding (211, 56.3%). Main pathology findings were endometrial polyps (172, 45.9%) and submucous myomas (105, 28%). Polyps had histologic abnormalities in 18 patients. Sensitivity of preoperative diagnostic tools for all intrauterine abnormalities and specifically for myomas and polyps was TVS 74% and 39%, SIS 96% and 96%, hysteroscopy 100% and 99%, and Pipelle biopsy 24% and 10%. The complication rate was 1.3%. Postmenopausal women felt significantly more improvement in symptoms (p = 0.02), and were more satisfied (p 相似文献   

Comparison of transvaginal ultrasound, saline infusion sonography and hysteroscopy to investigate postmenopausal bleeding and unscheduled bleeding on HRT

A study was conducted to compare transvaginal ultrasound (TVS), saline infusion sonography (SIS) and outpatient hysteroscopy for examining the uterine cavity in women with postmenopausal bleeding and unscheduled bleeding on hormone replacement therapy (HRT). Fourty Subjects agreed to undergo TVS, SIS and hysteroscopy in addition to endometrial sampling. The abnormalities detected by each imaging method were recorded together with the discomfort (visual analogue scale). Thirty women completed all three imaging procedures. In 18 cases TVS suggested an abnormal cavity. SIS and hysteroscopy were of similar efficacy in clarifying the nature of this, and confirmed an abnormality in 12 cases (40%). TVS was significantly less painful than the other procedures (p < 0.001). SIS and hysteroscopy were associated with pain scores similar to endometrial sampling. These findings justify the need for a large randomised trial of TVS, SIS, hysteroscopy and endometrial sampling, in order to develop the most appropriate strategy for investigating postmenopausal bleeding and unscheduled bleeding on HRT.     

The value of sonohysterography in detecting intracavitary benign abnormalities

The aim of this retrospective study was to assess the diagnostic value and the usefulness of sonohysterography in the detection of uterine intracavitary benign abnormalities, compared with other diagnostic methods (transvaginal ultrasonography and diagnostic hysteroscopy). From January 2003 to December 2003, a total of 73 patients (47 premenopausal (middle age 38.9) and 26 postmenopausal women (middle age 60.5)) underwent transvaginal ultrasonography (TVS) and sonohysterography (SHG), consisting of an intrauterine infusion of saline solution during transvaginal ultrasound. The women referred to our Ultrasonography Center because of intermenstrual (38) or postmenopausal bleeding (19), or an abnormal or a poorly defined endometrial interface (16) as seen as baseline ultrasonography. The findings at TVS and SHG were compared with hysteroscopy (HS). In one case, the SHG was technically impossible to perform. In premenopausal group the sensitivity of SHG had been 100% in detecting submucosal fibroids, endometrial polyps and hyperplasia and 75% in detecting normal uterus. The specificity had been always 100%. In postmenopausal group the sensitivity of SHG had been 75% in detecting submucosal fibroids, 93.8% in endometrial polyps and 100% in hyperplasia and normal uterus. The specificity had been 100% in submucosal fibroids and hyperplasia and had been 90.0 and 95.5% in endometrial polyps and normal uterus, respectively. SHG allows to obtain a precise diagnosis of benign uterine pathology and it is more accurate in the diagnosis of intracavitary abnormalities than that obtained by TVS. Preoperative use of SHG may assist in choosing the best surgical treatment for the patient.     

Hysteroscopic evaluation of the endometrium in postmenopausal women taking tamoxifen

STUDY OBJECTIVE: To evaluate hysteroscopic endometrial changes due to tamoxifen therapy in postmenopausal women with breast cancer. DESIGN: Retrospective study (Canadian Task Force classification II-2). SETTING: University-affiliated hospital. Patients. Eighty-eight postmenopausal women (or with iatrogenic amenorrhea) receiving tamoxifen 20 mg/day for at least 1 year for breast cancer. INTERVENTION: Record review of patients undergoing transvaginal sonography (TVS) and office hysteroscopy with eye-directed biopsy specimens obtained with a 5-mm, continuous-flow, operative hysteroscope. MEASUREMENTS AND MAIN RESULTS: Patients with thickened endometrium and pathologic findings at hysteroscopy had taken tamoxifen for significantly longer times than those without such findings (p < 0.05). CONCLUSION: Our findings confirm the estrogenic effect of tamoxifen on endometrium. Endometrial evaluation by TVS suggests further diagnostic procedures, but only hysteroscopy allows the surgeon to visualize endometrial lesions and obtain eye-directed biopsy tissue.     

Transvaginal endometrial sonography in postmenopausal women taking tamoxifen

OBJECTIVE: To evaluate sonographic measurements of endometrial thickness in postmenopausal women taking adjuvant tamoxifen therapy for breast cancer, and to correlate sonographic and pathologic findings to symptoms and duration of tamoxifen therapy. METHODS: Medical records and sonograms of 80 postmenopausal women treated for breast cancer with adjuvant tamoxifen therapy were reviewed retrospectively. Endometrial thickness was recorded as a single-layer thickness and considered abnormal when greater than 2.5 mm for postmenopausal women. Sonographic endometrial thickness was correlated to histologic findings, symptoms, and duration of tamoxifen therapy. RESULTS: Fifty-seven of 80 postmenopausal women (69%) had single-layer endometrial thicknesses of 2.5 mm or greater, measured by transvaginal sonography, and 55 of 57 had endometrial biopsies or dilatations and curettage. Biopsies detected 24 cases of abnormal endometria, including endometrial carcinoma (two), breast carcinoma metastatic to the endometrium (one), endometrial polyps (13), tubal metaplasia (three), and benign endometrial hyperplasia (five). Using a single-layer endometrial thickness greater than 2.5 mm by transvaginal ultrasound, 21 of 24 (87.5%) women with abnormal endometria were detected. Women with abnormal pathologic findings had a significantly thicker mean single-layer endometrial thickness than those with normal findings, 7 mm versus 4 mm (P < .01). Twelve women had postmenopausal bleeding, all of whom had a single-layer endometrial thickness greater than 2.5 mm on transvaginal sonography. CONCLUSION: With a sensitivity of detecting endometrial abnormalities of 84%, transvaginal sonography was useful for studying postmenopausal tamoxifen-treated women.     

宫腔镜诊治宫内占位性疾病1065例临床分析

目的:探讨宫腔镜检查与阴道彩色超声(TVB)对宫内占位性疾病的诊治价值。方法:回顾性分析因不孕、绝经后出血、阴道彩色超声提示宫腔占位等不同原因行宫腔镜检查的1 065例患者,根据宫腔镜检查结果,了解TVB诊断的准确率及宫腔占位性疾病的病理性质。结果:1 065例宫腔镜检查的患者术前TVB提示有宫内占位的为800例,经宫腔镜检查,术中见宫内占位900例,2种检查方法相比,差异无统计学意义(P0.05)。术前TVB提示有宫内占位的800例患者中,经宫腔镜检查证实有宫内占位750例,TVB与宫腔镜检查的阳性符合率为93.8%(750/800),假阳性率为6.2%(50/800)。术前TVB未提示宫内占位的265例患者中,经宫腔镜检查存在宫内占位的有150例,TVB的假阴性率为10.8%(115/1 065)。宫腔镜术后病理诊断提示,宫腔内膜息肉670例,占62.9%(670/1 065),子宫黏膜下肌瘤121例,占11.4%(121/1065),内膜简单性增生153例,占14.4%(153/1 065),内膜功能性增生93例,占8.7%(93/1 065),复杂性增生9例,占0.8%(9/1 065),不典型增生8例,占0.8%(8/1 065),子宫内膜癌11例,占1.0%(11/1 065)。结论:准确诊断宫内占位性疾病性质,须在宫腔镜直视下检查并取材进行病理诊断,此是宫内占位性疾病的最终诊断结果。